{
    "clinical_study": {
        "@rank": "2985", 
        "arm_group": [
            {
                "arm_group_label": "warfarin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "aspirin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "In this study, the investigators examine whether aspirin or warfarin is useful for atrial\n      fibrillation patients with chronic kidney disease."
        }, 
        "brief_title": "Warfarin Versus Aspirin in Patients With Atrial Fibrillation and Chronic Kidney Disease", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Chronic Kidney Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "randomised open labelled prospective study\n\n      We enroll patients with CHADS2 score 1 non-valvular AF with chronic kidney disease, and\n      analyze all thromboembolic event or major bleeding event during follow-up period. Warfarin\n      group take dose adjusted warfarin (target INR 2.0-3.0) and aspirin group take aspirin 100mg\n      daly.\n\n      Thromboembolic events: Ischemic stroke or systemic arterial occlusion Major bleeding:\n      gastrointestinal bleeding or intracranial bleeding (code 430, code 431, code 432 by ICD-9-CM\n      codes)\n\n      -> Only the first event of each case will be used for the analysis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  CHADS2 score 1 nonvalvular atrial fibrillation patients with chronic kidney disease\n\n        Exclusion Criteria:\n\n          -  HAS-BLED \u226530\n\n          -  History of syncope or seizure within 1 year\n\n          -  History of major bleeding event within 6 months\n\n          -  BP>180/100\n\n          -  Abnormal prothrombin time\n\n          -  Hypersensitivity of  aspirin or warfarin\n\n          -  Folstein mini mental state examination score <26\n\n          -  Taking or had taken other anticoagulants"
            }, 
            "gender": "Both", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "720", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668901", 
            "org_study_id": "WASAK"
        }, 
        "intervention": [
            {
                "arm_group_label": "warfarin", 
                "intervention_name": "warfarin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "aspirin", 
                "intervention_name": "aspirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Warfarin"
            ]
        }, 
        "keyword": [
            "warfarin", 
            "aspirin"
        ], 
        "lastchanged_date": "August 20, 2012", 
        "location": {
            "contact": {
                "email": "seil@snu.ac.kr", 
                "last_name": "Seil Oh, MD, PhD,FHRS", 
                "phone": "82-2-2072-2088"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul Nationap University Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Prospective Trial of Warfarin Versus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation and Chronic Kidney Disease", 
        "overall_contact": {
            "email": "seil@snu.ac.kr", 
            "last_name": "Seil Oh, MD,PhD,FHRS", 
            "phone": "82-2-2072-2088"
        }, 
        "overall_contact_backup": {
            "email": "chamj81@gmail.com", 
            "last_name": "Myung-jin Cha, MD", 
            "phone": "82-10-9070-4090"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Thromboembolic event"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668901"
        }, 
        "secondary_outcome": {
            "measure": "Major bleeding", 
            "safety_issue": "Yes"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}